Centessa Pharmaceuticals plc is a clinical-stage biotechnology company developing small molecule orexin receptor 2 (OX2R) agonists for neuroscience diseases. Its lead candidate, cleminorexton, is in late-stage clinical development for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). The company also advances follow-up candidates ORX142 and ORX489 for neurodegenerative and neuropsychiatric disorders, leveraging proprietary structure-based drug design and a collaboration with Nxera for stabilized OX2R protein access.
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001847903-26-000025 | EDGAR | 114K words |
| 2025-03-24 | 2024-12-31 | 0001847903-25-000051 | EDGAR | 124K words |
| 2024-03-28 | 2023-12-31 | 0001847903-24-000054 | EDGAR | 128K words |
| 2023-03-30 | 2022-12-31 | 0001847903-23-000063 | EDGAR | 138K words |
| 2022-03-30 | 2021-12-31 | 0001847903-22-000022 | EDGAR | 141K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001847903-25-000156 | EDGAR | 74K words |
| 2025-08-12 | 2025-06-30 | 0001847903-25-000135 | EDGAR | 74K words |
| 2025-05-14 | 2025-03-31 | 0001847903-25-000072 | EDGAR | 72K words |
| 2024-11-12 | 2024-09-30 | 0001847903-24-000167 | EDGAR | 79K words |
| 2024-08-13 | 2024-06-30 | 0001847903-24-000128 | EDGAR | 79K words |
| 2024-05-13 | 2024-03-31 | 0001847903-24-000081 | EDGAR | 76K words |
| 2023-11-13 | 2023-09-30 | 0001847903-23-000189 | EDGAR | 81K words |
| 2023-08-14 | 2023-06-30 | 0001847903-23-000155 | EDGAR | 80K words |
| 2023-05-12 | 2023-03-31 | 0001847903-23-000097 | EDGAR | 78K words |
| 2022-11-10 | 2022-09-30 | 0001847903-22-000084 | EDGAR | 79K words |
| 2022-08-10 | 2022-06-30 | 0001847903-22-000049 | EDGAR | 78K words |
| 2022-05-16 | 2022-03-31 | 0001847903-22-000031 | EDGAR | 75K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134656 | EDGAR | 75K words |
| 2026-02-13 | 0001193125-26-051424 | EDGAR | 1K words |
| 2025-12-11 | 0001193125-25-315074 | EDGAR | 2K words |
| 2025-11-24 | 0001193125-25-292015 | EDGAR | 30K words |
| 2025-11-13 | 0001193125-25-278827 | EDGAR | 1K words |
| 2025-11-05 | 0001847903-25-000154 | EDGAR | 4K words |
| 2025-08-12 | 0001847903-25-000133 | EDGAR | 3K words |
| 2025-06-20 | 0001847903-25-000093 | EDGAR | 1K words |
| 2025-06-17 | 0001847903-25-000090 | EDGAR | 1K words |
| 2025-05-29 | 0001847903-25-000081 | EDGAR | 1K words |
103 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001847903 |
| Ticker | CNTA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
| Website | https://www.centessa.com |
| Listed | 2021-05-28 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CNTA (~200 tokens, structured JSON with cryptographic provenance)